Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ischemic Heart Disease

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 139 articles:
HTML format



Single Articles


    September 2022
  1. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    PubMed     Abstract available


  2. JI M, Li Y, Liu Y, Ma G, et al
    Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats.
    J Cardiovasc Pharmacol. 2022;80:442-452.
    PubMed     Abstract available


  3. CHEN JY, Li T, Wang JL, Wang ZL, et al
    Protective Effects and Mechanisms of Melatonin on Stress Myocardial Injury in Rats.
    J Cardiovasc Pharmacol. 2022;80:417-429.
    PubMed     Abstract available


    August 2022
  4. ENNEZAT PV, Guerbaai RA, Marechaux S, Le Jemtel TH, et al
    Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00106.
    PubMed     Abstract available


  5. YANG S, Shen W, Zhang HZ, Wang CX, et al
    Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00107.
    PubMed     Abstract available


  6. AMIN G, Massoud G, Fares S, Booz GW, et al
    Colchicine and acute coronary syndromes: a new trick for an old drug?
    J Cardiovasc Pharmacol. 2022 Aug 18. pii: 00005344-990000000-00100.
    PubMed    


  7. HUI J, Bai T, Liang L, He Q, et al
    Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00094.
    PubMed     Abstract available


  8. BURASHNIKOV A, Abbate A, Booz GW
    Cardiovascular complications of anti-cancer therapy: a developing storm in medicine.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00095.
    PubMed    


  9. ANTO S, Sathish V, Sun C, O'Rourke ST, et al
    Apelin-Induced Relaxation of Coronary Arteries is Impaired in a Model of Second-Hand Cigarette Smoke Exposure.
    J Cardiovasc Pharmacol. 2022 Aug 11. pii: 00005344-990000000-00093.
    PubMed     Abstract available


  10. CALCAGNO S, Corcione N, Biondi-Zoccai G, Giordano A, et al
    De-Escalation of Dual Antiplatelet Therapy: Will We Ever Get to the Right Method?
    J Cardiovasc Pharmacol. 2022;80:203-205.
    PubMed    


    July 2022
  11. PEPE M, Napoli G, Biondi-Zoccai G, Giordano A, et al
    Anti-inflammatory therapy for acute coronary syndromes: is it time for a shift in the treatment paradigm?
    J Cardiovasc Pharmacol. 2022 Jul 20. pii: 00005344-990000000-00085.
    PubMed    


  12. SHARMA P, Sharma N
    Advances in Nano-formulated Polyphenols for Protection against Cardiovascular diseases.
    J Cardiovasc Pharmacol. 2022 Jul 18. pii: 00005344-990000000-00082.
    PubMed     Abstract available


  13. VAN TASSELL BW, Wohlford GF, Del Buono MG, Damonte JI, et al
    Safety, tolerability and effects of a single subcutaneous administration of SP16-a SERPIN-like, small peptide agonist of the Low-Density Lipoprotein-like Receptor 1 -on the acute inflammatory response in patients with ST-segment elevation Myocardial I
    J Cardiovasc Pharmacol. 2022 Jul 12. pii: 00005344-990000000-00079.
    PubMed     Abstract available


  14. YANG G, Gai X, Han M, Gao F, et al
    Aberrant circulating SNHG1 serves as a biomarker to distinguish acute myocardial infarction and construction of a risk model for secondary heart failure.
    J Cardiovasc Pharmacol. 2022 Jul 11. pii: 00005344-990000000-00043.
    PubMed    


  15. AKANDE O, Chen Q, Cholyway R, Toldo S, et al
    Modulation of Mitochondrial Respiration During Early Reperfusion Reduces Cardiac Injury in Donation After Circulatory Death Hearts.
    J Cardiovasc Pharmacol. 2022;80:148-157.
    PubMed     Abstract available


    June 2022
  16. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    PubMed     Abstract available


  17. BAO YL, Gu LF, Du C, Wang YX, et al
    Evaluating the utility of colchicine in acute coronary syndrome: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00068.
    PubMed     Abstract available


    May 2022
  18. SOTHIVELR V, Hasan MY, Saffian SM, Zainalabidin S, et al
    Revisiting miRNA-21 as a Therapeutic Strategy for Myocardial Infarction: A Systematic Review.
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00055.
    PubMed     Abstract available


  19. LYCOURAS MM, Clark CM, Mills K, Gupta A, et al
    Early versus late administration of P2Y12 inhibitors in non-ST segment elevation myocardial infarction and delayed cardiac catherization.
    J Cardiovasc Pharmacol. 2022 May 13. pii: 00005344-990000000-00051.
    PubMed     Abstract available


  20. ZHONG PY, Shang YS, Bai N, Ma Y, et al
    Dual antiplatelet therapy after drug-eluting stents implantation in East Asians: a network meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2022 May 6. pii: 00005344-990000000-00042.
    PubMed     Abstract available


  21. SHANG YS, Zhong PY, Ma Y, Bai N, et al
    Efficacy and Safety of Proton Pump Inhibitors in Patients with Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2022 May 4. pii: 00005344-990000000-00036.
    PubMed     Abstract available


  22. XUE K, Chen S, Chai J, Yan W, et al
    Upregulation of Periostin Through CREB Participates in Myocardial Infarction-induced Myocardial Fibrosis.
    J Cardiovasc Pharmacol. 2022;79:687-697.
    PubMed     Abstract available


    April 2022
  23. DENNY O, Woodruff AE, Mills K, Chilbert MR, et al
    Comparison of ischemic and bleeding events between short versus long duration tirofiban regimens in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00037.
    PubMed     Abstract available


  24. GITTO M, Kotinas AS, Terzi R, Oliva A, et al
    Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.
    J Cardiovasc Pharmacol. 2022 Apr 14. pii: 00005344-990000000-00025.
    PubMed     Abstract available


  25. SHAN C, Degryse B, Tolan P, Custaud MA, et al
    Pleiotropic effects of Icariside II on the cardiovascular system: Novel applications of ethnopharmacology in targeting vascular remodelling.
    J Cardiovasc Pharmacol. 2022 Apr 12. pii: 00005344-990000000-00024.
    PubMed    


  26. BAI N, Ma Y, Niu Y, Zhong PY, et al
    Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Apr 8. pii: 00005344-990000000-00022.
    PubMed     Abstract available


  27. ADEVA-ANDANY MM, Fernandez-Fernandez C, Carneiro-Freire N, Castro-Quintela E, et al
    Cardiovascular protection associated with cilostazol, colchicine and target of rapamycin inhibitors.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00019.
    PubMed     Abstract available


  28. DAI H, Zhao N, Zheng Y
    CircLDLR modulates the proliferation and apoptosis of vascular smooth muscle cells in coronary artery disease through miR-26-5p/KDM6A axis.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00018.
    PubMed     Abstract available


  29. AKYILDIZ AG, Biondi-Zoccai G, De Biase D
    Impact of the Gastrointestinal Tract Microbiota on Cardiovascular Health and Pathophysiology.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00021.
    PubMed     Abstract available


  30. VLACHAKIS PK, Varlamos C, Benetou DR, Kanakakis I, et al
    Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2022;79:407-419.
    PubMed     Abstract available


  31. DENG X, Liu Y, Xu Z, Wang Z, et al
    lncRNA Nuclear Factor of Activated T Cells Knockdown Alleviates Hypoxia/Reoxygenation-induced Cardiomyocyte Apoptosis by Upregulating HIF-1alpha Expression.
    J Cardiovasc Pharmacol. 2022;79:479-488.
    PubMed     Abstract available


    March 2022
  32. BROMAGE DI, Pareek N, Cannata A, Ameri P, et al
    Targeting inflammation after myocardial infarction - another piece of the puzzle.
    J Cardiovasc Pharmacol. 2022 Mar 15. pii: 00005344-990000000-00009.
    PubMed    


  33. ZHOU S, Liu P, Zhang G, Cheng Z, et al
    HDAC1 depletion alleviates coronary heart disease via the microRNA-182-mediated TGF-beta/Smad signaling pathway.
    J Cardiovasc Pharmacol. 2022 Mar 11. pii: 00005344-990000000-00008.
    PubMed     Abstract available


  34. HU MJ, Tan JS, Gao XJ, Yang JG, et al
    De-Escalation of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: An Updated Meta-Analysis and Trial Sequential Analysis of 21 studies and 38741 patients.
    J Cardiovasc Pharmacol. 2022 Mar 4. pii: 00005344-990000000-00029.
    PubMed     Abstract available


  35. POLETTO BONETTO JH, Luz de Castro A, Fernandes RO, Corssac GB, et al
    Sulforaphane Effects on Cardiac Function and Calcium-Handling-Related Proteins in 2 Experimental Models of Heart Disease: Ischemia-Reperfusion and Infarction.
    J Cardiovasc Pharmacol. 2022;79:325-334.
    PubMed     Abstract available


    February 2022
  36. BERGH N, Myredal A, Nivedahl P, Petzold M, et al
    Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Feb 14. pii: 00005344-900000000-98046.
    PubMed     Abstract available


  37. XU H, Tilley DG
    Pepducin-mediated GPCR signaling in the cardiovascular system.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98051.
    PubMed     Abstract available


  38. DEL BUONO MG, Damonte JI, Chiabrando JG, Markley R, et al
    Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98049.
    PubMed     Abstract available


  39. BEAVERS CJ, Effoe SA, Dobesh PP
    Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
    J Cardiovasc Pharmacol. 2022;79:161-167.
    PubMed     Abstract available


    January 2022
  40. MA Y, Zhong PY, Shang YS, Bai N, et al
    Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Jan 27. pii: 00005344-900000000-98056.
    PubMed     Abstract available


  41. CIZMAROVA B, Evinova A, Racay P, Birkova A, et al
    The effect of oestrogen supplementation on antioxidant enzymes and mitochondrial respiratory function after myocardial infarction of ovariectomized rats.
    J Cardiovasc Pharmacol. 2022 Jan 21. pii: 00005344-900000000-98057.
    PubMed     Abstract available


  42. KIM Y, Byun S, Kim HY, Kim DB, et al
    Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era - systemic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98062.
    PubMed     Abstract available


  43. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    PubMed     Abstract available


  44. AL-ANI MA, Murray MR, Taha MB, Meece L, et al
    Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
    J Cardiovasc Pharmacol. 2022 Jan 17. pii: 00005344-900000000-98060.
    PubMed     Abstract available


    December 2021
  45. WANG K, Tang R, Wang S, Xiong Y, et al
    Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.
    J Cardiovasc Pharmacol. 2021 Dec 28. pii: 00005344-900000000-98074.
    PubMed     Abstract available


  46. LIU X, Qi K, Gong Y, Long X, et al
    Ferulic Acid Alleviates Myocardial Ischemia Reperfusion Injury Via Upregulating AMPKalpha2 Expression-Mediated Ferroptosis Depression.
    J Cardiovasc Pharmacol. 2021;79:489-500.
    PubMed     Abstract available


  47. SHRESTHA DB, Budhathoki P, Sedhai YR, Khadka M, et al
    Colchicine for patients with coronary artery disease: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98085.
    PubMed     Abstract available


  48. BRAGA CL, Acquarone M, da C Arona V, Osorio BS, et al
    Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19?
    J Cardiovasc Pharmacol. 2021 Dec 10. pii: 00005344-900000000-98080.
    PubMed     Abstract available


  49. GODO S, Takahashi J, Yasuda S, Shimokawa H, et al
    Endothelium in Coronary Macrovascular and Microvascular Diseases.
    J Cardiovasc Pharmacol. 2021;78.
    PubMed     Abstract available


  50. SAYED-PATHAN NI, Kumar P, Paknikar KM, Gajbhiye V, et al
    MicroRNAs: A Neoteric Approach to Understand Pathogenesis, Diagnose, and Treat Myocardial Infarction.
    J Cardiovasc Pharmacol. 2021;78:773-781.
    PubMed     Abstract available


  51. YANG J, Xiang Z, Zhang J, Yang J, et al
    miR-24 Alleviates MI/RI by Blocking the S100A8/TLR4/MyD88/NF-kB Pathway.
    J Cardiovasc Pharmacol. 2021;78:847-857.
    PubMed     Abstract available


    November 2021
  52. MA Y, Zhong PY, Shang YS, Bai N, et al
    Efficacy and Safety of Short-Term Dual Antiplatelet Therapy in East Asians: A Systematic Review and a Meta-Analysis of Randomized Clinical Trials.
    J Cardiovasc Pharmacol. 2021;79:264-272.
    PubMed     Abstract available


  53. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    PubMed     Abstract available


  54. WINGLER LM, Feld AP
    Nanobodies as probes and modulators of cardiovascular GPCRs.
    J Cardiovasc Pharmacol. 2021 Nov 19. pii: 00005344-900000000-98107.
    PubMed     Abstract available


  55. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available


  56. GRAGNANO F, Calabro P, Cattano D
    CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98112.
    PubMed    


  57. CATURANO A, Spiezia S, Sasso FC
    Statin effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Haemodialysis.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98118.
    PubMed    


  58. LI X, Dang Y
    Inhibition of GARS1-DT Protects Against Hypoxic Injury in H9C2 Cardiomyocytes via Sponging miR-212-5p.
    J Cardiovasc Pharmacol. 2021;78:e714-e721.
    PubMed     Abstract available


    October 2021
  59. ZHANG Y, Zhao X, Ye Y, Li Q, et al
    Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98125.
    PubMed     Abstract available


  60. MELITA H, Manolis AA, Manolis TA, Manolis AS, et al
    Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98128.
    PubMed     Abstract available


  61. HORIKOSHI T, Nakamura T, Yoshizaki T, Nakamura J, et al
    Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98138.
    PubMed     Abstract available


  62. ASSMANN AK, Goschmer D, Sugimura Y, Chekhoeva A, et al
    A role for peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists in counteracting the degeneration of cardiovascular grafts.
    J Cardiovasc Pharmacol. 2021 Oct 4. pii: 00005344-900000000-98134.
    PubMed     Abstract available


  63. WANG X, Sun Q, Hu W
    Carvedilol Protects Against the H2O2-induced Cell Damages in Rat Myoblasts by Regulating the Circ_NFIX/miR-125b-5p/TLR4 Signal Axis.
    J Cardiovasc Pharmacol. 2021;78:604-614.
    PubMed     Abstract available


    September 2021
  64. DU X, Ma Z, Li L, Zhong X, et al
    Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
    J Cardiovasc Pharmacol. 2021;78:e675-e680.
    PubMed     Abstract available


  65. WANG S, Li L, Deng W, Jiang M, et al
    CircRNA MFACR is upregulated in myocardial infarction and downregulates miR-125b to promote cardiomyocyte apoptosis induced by hypoxia.
    J Cardiovasc Pharmacol. 2021 Sep 13. pii: 00005344-900000000-98152.
    PubMed     Abstract available


  66. WEI H, Xue Q, Sun L, Lv J, et al
    BRD4 inhibition protects against myocardial ischemia/reperfusion injury by suppressing inflammation and oxidative stress through PI3K/AKT signaling pathway.
    J Cardiovasc Pharmacol. 2021 Sep 8. pii: 00005344-900000000-98150.
    PubMed     Abstract available


  67. LOPEZ AE, Bauza MDR, Cuniberti L, Crottogini AJ, et al
    Gene Therapy: Targeting Cardiomyocyte Proliferation to Repopulate the Ischemic Heart.
    J Cardiovasc Pharmacol. 2021;78:346-360.
    PubMed     Abstract available


  68. ZHANG DM, Chen SL
    Potential Mechanisms of In-stent Neointimal Atherosclerotic Plaque Formation.
    J Cardiovasc Pharmacol. 2021;78:388-393.
    PubMed     Abstract available


    August 2021
  69. DIAZ-CANESTRO C, Xu A
    The impact of different adipose depots on cardiovascular disease.
    J Cardiovasc Pharmacol. 2021 Aug 19. pii: 00005344-900000000-98098.
    PubMed     Abstract available


  70. LIU XW, Lu MK, Zhong HT, Liu JJ, et al
    Panax Notoginseng Saponins Protect H9c2 Cells From Hypoxia-reoxygenation Injury Through the Forkhead Box O3a Hypoxia-inducible Factor-1 Alpha Cell Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:e681-e689.
    PubMed     Abstract available


  71. JI P, Song X, Lv Z
    Knockdown of circ_0004104 Alleviates Oxidized Low-Density Lipoprotein-Induced Vascular Endothelial Cell Injury by Regulating miR-100/TNFAIP8 Axis.
    J Cardiovasc Pharmacol. 2021;78:269-279.
    PubMed     Abstract available


  72. YUAN M, Wu B, Zhang L, Wang H, et al
    CD40L/CD40 Regulates Adipokines and Cytokines by H3K4me3 Modification in Epicardial Adipocytes.
    J Cardiovasc Pharmacol. 2021;78:228-234.
    PubMed     Abstract available


    July 2021
  73. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    PubMed    


  74. LI Y, Meng W, Hou Y, Li D, et al
    Dual Role of Mitophagy in Cardiovascular Diseases.
    J Cardiovasc Pharmacol. 2021;78:e30-e39.
    PubMed     Abstract available


  75. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    PubMed     Abstract available


  76. YIN CL, Liu X, Wang HX, Yan MC, et al
    Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability.
    J Cardiovasc Pharmacol. 2021;78:e147-e155.
    PubMed     Abstract available


  77. CAI X, Li B, Wang Y, Zhu H, et al
    CircJARID2 Regulates Hypoxia-Induced Injury in H9c2 Cells by Affecting miR-9-5p-Mediated BNIP3.
    J Cardiovasc Pharmacol. 2021;78:e77-e85.
    PubMed     Abstract available


  78. CARBONE A, Bottino R, Russo V, D'Andrea A, et al
    Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports.
    J Cardiovasc Pharmacol. 2021;78:e20-e29.
    PubMed     Abstract available


    June 2021
  79. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available


  80. HAO L, Wang J, Bi SJ, Cheng C, et al
    Upregulation of lncRNA FGD5-AS1 ameliorates myocardial ischemia/reperfusion injury via miR-106a-5p and miR-106b-5p.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98185.
    PubMed     Abstract available


  81. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    PubMed     Abstract available


  82. ZHANG J, Tang Y, Zhang J, Wang J, et al
    CircRNA ACAP2 is overexpressed in myocardial infarction and promotes the maturation of miR-532 to induce the apoptosis of cardiomyocyte.
    J Cardiovasc Pharmacol. 2021 Jun 15. pii: 00005344-900000000-98198.
    PubMed     Abstract available


  83. LI Y, Ren X, Fang Z
    Systematic Review and Meta-analysis: The Effects of Prophylactic Proton Pump Inhibitor Treatment in Patients With Coronary Heart Disease Receiving Dual Antiplatelet Therapy.
    J Cardiovasc Pharmacol. 2021;77:835-861.
    PubMed     Abstract available


  84. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available


  85. PASCALE JV, Lucchesi PA, Garcia V
    Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
    J Cardiovasc Pharmacol. 2021;77:707-717.
    PubMed     Abstract available


  86. ZHANG Y, Nie H, Li S, Deng Y, et al
    Carbon Monoxide-Saturated Polymerized Placenta Hemoglobin Optimizes Mitochondrial Function and Protects Heart Against Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2021;77:814-821.
    PubMed     Abstract available


  87. YE G, Wang S, Peng D
    Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:787-795.
    PubMed     Abstract available


    May 2021
  88. LIU X, Hua Y, Hu M, Wu K, et al
    Knockdown of lncRNA Abhd11os attenuates myocardial ischemia/reperfusion injury by inhibiting apoptosis in cardiomyocytes.
    J Cardiovasc Pharmacol. 2021 May 31. pii: 00005344-900000000-98212.
    PubMed     Abstract available


  89. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
    A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
    J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
    PubMed     Abstract available


  90. IQBAL J, Chamberlain J, Alfaidi M, Hughes M, et al
    Carbon monoxide releasing molecule A1 reduces myocardial damage after acute myocardial infarction in a porcine model.
    J Cardiovasc Pharmacol. 2021 May 20. pii: 00005344-900000000-98224.
    PubMed     Abstract available


  91. YUAN JL, Yin CY, Li YZ, Song S, et al
    EZH2 as an epigenetic regulator of cardiovascular development and diseases.
    J Cardiovasc Pharmacol. 2021 May 19. pii: 00005344-900000000-98225.
    PubMed     Abstract available


  92. CATURANO A
    Bivalirudin use for Primary Percutaneous Coronary Intervention on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 May 5. pii: 00005344-900000000-98249.
    PubMed    


  93. YANG T, Gu J, Du C, Shan T, et al
    Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review.
    J Cardiovasc Pharmacol. 2021;77:549-556.
    PubMed     Abstract available


  94. MA B, Zhao M, Guo Z
    Circular RNA circ_0010729 Knockdown Attenuates Oxygen-Glucose Deprivation-Induced Human Cardiac Myocytes Injury by miR-338-3p/CALM2 Axis.
    J Cardiovasc Pharmacol. 2021;77:594-602.
    PubMed     Abstract available


  95. LIU S, Liao Q, Xu W, Zhang Z, et al
    MiR-129-5p Protects H9c2 Cardiac Myoblasts From Hypoxia/Reoxygenation Injury by Targeting TRPM7 and Inhibiting NLRP3 Inflammasome Activation.
    J Cardiovasc Pharmacol. 2021;77:586-593.
    PubMed     Abstract available


    April 2021
  96. JAGADISH PS, Le FK, Labroo A, Nasr A, et al
    A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 Apr 22. pii: 00005344-900000000-98253.
    PubMed     Abstract available


  97. PENG Q, Li L, Bi X
    Long non-coding RNA SNHG7 knockdown protects mouse cardiac fibroblasts against myocardial infarction by regulating miR-455-3p/PTAFR axis.
    J Cardiovasc Pharmacol. 2021 Apr 21. pii: 00005344-900000000-98257.
    PubMed     Abstract available


  98. LEE CC, Chen WT, Chen SY, Lee TM, et al
    Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats.
    J Cardiovasc Pharmacol. 2021;77:745-755.
    PubMed     Abstract available


  99. SALLAM MY, El-Gowilly SM, El-Mas MM
    Cardiac and brainstem neuroinflammatory pathways account for androgenic incitement of cardiovascular and autonomic manifestations in endotoxic male rats.
    J Cardiovasc Pharmacol. 2021 Apr 9. pii: 00005344-900000000-98265.
    PubMed     Abstract available


  100. LU Y, Yuan W, Wang L, Ning M, et al
    Contribution of lncRNA CASC8, CASC11 and PVT1 genetic variants to the susceptibility of coronary heart disease.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98242.
    PubMed     Abstract available


  101. JIAO F, Varghese K, Wang S, Liu Y, et al
    Recent Insights into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98240.
    PubMed     Abstract available



  102. Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases: Erratum.
    J Cardiovasc Pharmacol. 2021;77:529.
    PubMed    


  103. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    PubMed     Abstract available


  104. YASHIMA F, Inohara T, Nishida H, Shimoji K, et al
    In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
    J Cardiovasc Pharmacol. 2021;78:221-227.
    PubMed     Abstract available


  105. TESTA A, Frati G, Versaci F, Biondi-Zoccai G, et al
    Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?
    J Cardiovasc Pharmacol. 2021;77:427-429.
    PubMed    


  106. SIMARD T, Motazedian P, Dhaliwal S, Di Santo P, et al
    Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021;77:450-457.
    PubMed     Abstract available


  107. DE BIASE D, Biondi-Zoccai G, Versaci F, Frati G, et al
    Management of Chronic Stable Angina: Modern Microbiomedical Research Provides Insights Into Traditional Chinese Medicine Treatments.
    J Cardiovasc Pharmacol. 2021;77:421-423.
    PubMed    


    March 2021
  108. SCHAUER A, Barthel P, Adams V, Linke A, et al
    Pharmacological Pre- and Postconditioning With Levosimendan Protect H9c2 Cardiomyoblasts From Anoxia/Reoxygenation-induced Cell Death via PI3K/Akt Signaling.
    J Cardiovasc Pharmacol. 2021;77:378-385.
    PubMed     Abstract available


  109. WANG H, Pang W, Xu X, You B, et al
    Cryptotanshinone Attenuates Ischemia/Reperfusion-induced Apoptosis in Myocardium by Upregulating MAPK3.
    J Cardiovasc Pharmacol. 2021;77:370-377.
    PubMed     Abstract available


  110. AIMO A, Egea OI, Emdin M, Bayes-Genis A, et al
    Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury.
    J Cardiovasc Pharmacol. 2021;77:332-333.
    PubMed     Abstract available


    February 2021
  111. VILHENA JC, Lopes de Melo Cunha L, Jorge TM, de Lucena Machado M, et al
    Acai reverses adverse cardiovascular remodeling in renovascular hypertension: a comparative effect with Enalapril.
    J Cardiovasc Pharmacol. 2021 Feb 19. pii: 00005344-900000000-98275.
    PubMed     Abstract available


  112. ZHAO X, Chen Y, Li L, Zhai J, et al
    Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
    J Cardiovasc Pharmacol. 2021;77:458-469.
    PubMed     Abstract available


  113. ZEYI Z, Ou C
    Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98271.
    PubMed     Abstract available


  114. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available


  115. ZHANG C, Jin DD, Wang XY, Lou L, et al
    Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
    J Cardiovasc Pharmacol. 2021;77:142-152.
    PubMed     Abstract available


    January 2021
  116. GRAGNANO F, Calabro P, Cattano D
    Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise.
    J Cardiovasc Pharmacol. 2021 Jan 13. pii: 00005344-900000000-98288.
    PubMed    


  117. LEMOINE MD, Christ T
    Human induced pluripotent stem cell derived cardiomyocytes: the new working horse in cardiovascular pharmacology?
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed    


  118. KAKAVAND H, Aghakouchakzadeh M, Coons J, Talasaz AH, et al
    Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    December 2020
  119. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  120. ABDU FA, Liu L, Mohammed AQ, Xu B, et al
    Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2020;76:678-683.
    PubMed     Abstract available


    November 2020
  121. WANG R, Peng L, Lv D, Shang F, et al
    Leonurine Attenuates Myocardial Fibrosis through Upregulation of miR-29a-3p in Mice Post-myocardial Infarction.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000957.
    PubMed     Abstract available


  122. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.
    PubMed    


  123. HUANG B, Xu C, Liu H, Deng W, et al
    In-Hospital Management and Outcomes of Acute Myocardial Infarction Before and During the Coronavirus Disease 2019 Pandemic.
    J Cardiovasc Pharmacol. 2020;76:540-548.
    PubMed     Abstract available


  124. MA H, Zheng L, Qin H, Wang W, et al
    Myocardial Infarction-associated Transcript Knockdown Inhibits Cell Proliferation, Migration, and Invasion Through miR-490-3p/Intercellular Adhesion Molecule 1 Axis in Oxidized Low-density Lipoprotein-induced Vascular Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2020;76:617-626.
    PubMed     Abstract available


  125. BHATTARAI M, Ibrahim AM, Salih M, Tandan N, et al
    Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Cont
    J Cardiovasc Pharmacol. 2020;76:574-583.
    PubMed     Abstract available


    October 2020
  126. ZHANG P, Yu Y, Wang P, Shen H, et al
    Role of Hydrogen Sulfide in Myocardial Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000943.
    PubMed     Abstract available


  127. SANGWOO P, Yong-Giun K, Soe Hee A, Hyun Woo P, et al
    Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker Based Optimal Medical Therapy after Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000930.
    PubMed     Abstract available


  128. CALCAGNO S, Di Pietro R, Biondi-Zoccai G, Versaci F, et al
    Renin-angiotensin blocking therapies: a must - but how? - after percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2020 Oct 23. doi: 10.1097/FJC.0000000000000941.
    PubMed    


  129. MUHAMMAD HAISUM M, Mahboob A, Dan A, Yochai B, et al
    Efficacy of Long-term Oral Beta-blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction with Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000922.
    PubMed     Abstract available


  130. QIU M, Ding LL, Wei XB, Liu SY, et al
    Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000916.
    PubMed     Abstract available


  131. NAJAFIPOUR H, Rostamzadeh F, Yeganeh-Hajahmadi M, Joukar S, et al
    Improvement of cardiac function in rats with myocardial infarction by low- to moderate-intensity endurance exercise is associated with normalization of Klotho and SIRT1.
    J Cardiovasc Pharmacol. 2020 Oct 15. doi: 10.1097/FJC.0000000000000935.
    PubMed     Abstract available


  132. ZHANG Y, Wen W, Liu H
    The Role of Immune Cells in Cardiac Remodeling After Myocardial Infarction.
    J Cardiovasc Pharmacol. 2020;76:407-413.
    PubMed     Abstract available


  133. ORTIZ VD, Turck P, Teixeira R, Bello-Klein A, et al
    Effects of carvedilol and thyroid hormones co-administration on apoptotic and survival proteins in the heart following acute myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000923.
    PubMed     Abstract available


  134. KRAUS L, Mohsin S
    Role of Stem Cell Derived Microvesicles in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000920.
    PubMed     Abstract available


    September 2020
  135. WANG Q, Liang C
    The Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients with Acute Coronary Syndrome.
    J Cardiovasc Pharmacol. 2020 Sep 24. doi: 10.1097/FJC.0000000000000914.
    PubMed     Abstract available


    August 2020
  136. MCGINLEY C, Mordi IR, Kelly P, Currie P, et al
    Prehospital Administration of Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Is Associated With Improved Long-Term Survival.
    J Cardiovasc Pharmacol. 2020;76:159-163.
    PubMed     Abstract available


  137. LIN Y, Huang S, Chen Y, Wu Z, et al
    Helix B Surface Peptide Protects Cardiomyocytes From Hypoxia/Reoxygenation-induced Autophagy Through the PI3K/Akt Pathway.
    J Cardiovasc Pharmacol. 2020;76:181-188.
    PubMed     Abstract available


    May 2020
  138. COLAREDA GA, Ragone MI, Bonazzola P, Consolini AE, et al
    The mKATP Channels and protein-kinase C Are Involved in the Cardioprotective Effects of Genistein on Estrogen-Deficient Rat Hearts Exposed to Ischemia/Reperfusion: Energetic Study.
    J Cardiovasc Pharmacol. 2020;75:460-474.
    PubMed     Abstract available


    April 2020
  139. ZHOU TT, Wang XY, Huang J, Deng YZ, et al
    Mitochondrial Translocation of DJ-1 Is Mediated by Grp75: Implication in Cardioprotection of Resveratrol Against Hypoxia/Reoxygenation-Induced Oxidative Stress.
    J Cardiovasc Pharmacol. 2020;75:305-313.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: